Breast Cancer
Conditions
Brief summary
This Study evaluates covariables being able to potentially influence the elimination of the monoclonal antibodies (trastuzumab, bevacizumab and denosumab).
Detailed description
Monoclonal antibodies are very widely used in cancer treatment . Certain patients benefit from these antibodies for several years and it is conceivable to wonder about the evolution of the pharmacokinetics of these antibodies.
Interventions
blood sample every 3 weeks
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* A diagnosed cancer * patient treated by bevacizumab or trastuzumab * Life expectancy of at least 3 months * For the women: menopausal women for at least 24 months, sterilized surgically, or, for the women old enough to procreate, use a method of effective contraception (oral contraceptives, contraceptive injections, intra-uterine devices, method of the double barrier, the contraceptive patches). This contraception will have to be pursued during 6 months after the end of the treatment by bevacizumab or by trastuzumab.
Exclusion criteria
* For Patients treated by trastuzumab: Dyspnoea of severe rest in touch with complications due to the disease or requiring an oxygen therapy. * Hypocalcemia severe untreated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clearance of the bevacizumab | 9 months |
Secondary
| Measure | Time frame |
|---|---|
| clearance of the trastuzumab | 9 months |
Countries
France
Outcome results
None listed